US pharma major Pfizer (NYSE: PFE) has announced that the black triangle safety warning for its smoking cessation drug Champix (varenicline) has been removed in the UK.
The drug, known as Chantix in the USA, has had its label updated in light of new data showing that it was not associated with an increased risk of serious neuropsychiatric adverse events, as had previously been claimed.
This data came from the largest ever randomized clinical trial of approved smoking cessation medicines, entitled EAGLES - Evaluating Adverse Events in a Global Smoking Cessation Study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze